Companies Kalaris Therapeutics, Inc.
Kalaris Therapeutics (ALVR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Kalaris Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,569,115FY2025
CEO total pay was $2,569,115 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $537,733 · bonus $0 · stock awards $0 · option awards $1,687,076
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Oxtoby | $537,733 | $0 | $0 | $1,687,076 | $344,306 | $0 | $0 | $2,569,115 |
| President and Chief Executive Officer | ||||||||
| Matthew Feinsod | 457,732 | 0 | 0 | 1,008,403 | 207,636 | 0 | 0 | 1,673,771 |
| Chief Medical Officer | ||||||||
| Brett Hagen | 397,301 | 67,814 | 0 | 295,417 | 121,512 | 0 | 557,130 | 1,439,174 |
| Chief Accounting Officer and AlloVir’s former Chief Accounting Officer | ||||||||
| Vikas Sinha | 81,106 | 0 | 0 | 0 | 0 | 0 | 1,019,848 | 1,100,954 |
| AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | ||||||||
| Matthew Gall | 80,833 | 0 | 0 | 949,279 | 34,495 | 0 | 0 | 1,064,607 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Andrew Oxtoby | $2,569,115 | — | — | — |
| Matthew Feinsod | 1,673,771 | — | — | — |
| Brett Hagen | 1,439,174 | 796,311 | — | ↑ +642,863 |
| Vikas Sinha | 1,100,954 | 544,400 | — | ↑ +556,554 |
| Matthew Gall | 1,064,607 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to attract, motivate, and retain executive officers by rewarding the achievement of near-term and longer-term financial and strategic goals. The program aligns executive interests with stockholders through a mix of cash and equity-based compensation, specifically using equity grants to create an ownership culture and promote retention via time-based vesting.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Feinsod | Option | 20,160 | 0.85 | — |
| Brett Hagen | Option | 50,262 | 7.31 | — |
| Matthew Feinsod | Option | 52,913 | 7.31 | — |
| Matthew Feinsod | Option | 101,000 | 7.31 | — |
| Matthew Gall | Option | 235,000 | 4.99 | — |
| Andrew Oxtoby | Option | 268,090 | 0.85 | — |
| Andrew Oxtoby | Option | 287,000 | 7.31 | — |
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,000 / 4,000 |
| Stock ownership guideline | — |
Peer group, and who names Kalaris Therapeutics as a peer
Companies that benchmark against ALVR
2 companies name ALVR as a compensation peer
- Atara Biotherapeutics, Inc.ATRAFY2024
- Atea Pharmaceuticals, Inc.AVIRFY2025
Each company listed discloses ALVR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALVR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Kalaris Therapeutics, Inc. | 2025 | Andrew Oxtoby | $537,733 | $0 | $1,687,076 | $344,306 | $2,569,115 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | 15,852,844 | 495,763 | 4,366 | 96.97% | Passed |
| 2025 | 2025-08-12 | — | — | — | — | — |
| 2024 | 2024-06-06 | — | — | — | — | — |
| 2023 | 2023-05-11 | — | — | — | — | — |
| 2022 | 2022-05-17 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-03 | 96.97%a |
| 2025 | 2025-08-12 | —b |
| 2024 | 2024-06-06 | —c |
a. Approved under the standard stated in the filing — “2-Advisory Vote on Executive Compensation The affirmative vote of the holders of shares of our common stock representing a majority of the votes properly cast on the matter is required for approval of the advisory vote on executive compensation. || Abstentions: Abstentions and broker non-votes (if any) will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Srinivas Akkaraju | Director | 2026-05-20 | A | 4,471 | $0 | $0 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-05-20 | A | 14,937 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-05-20 | D | 66,906 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-05-20 | A | 244,300 | 5 | 1,179,969 | Common, indirect | Form 4 ↗ |
| Leone D. Patterson | Director | 2026-06-03 | A | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Morana Jovan-Embiricos | Director | 2026-06-03 | A | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Dybbs | Director | 2026-06-03 | A | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Napoleone Ferrara | Director | 2026-06-03 | A | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Hallal | Director | 2026-06-03 | A | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anthony P. Adamis | Director | 2026-06-03 | A | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-06-03 | A | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Liisa Ann Bayko | Chief Financial Officer | 2026-07-20 | A | 220,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Keating | Director | 2026-08-01 | A | 18,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy O'Leary Vandekop | VP, Corporate Controller | 2026-08-27 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (25 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Andrew Oxtoby. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 28. As printed: 2,569,115. View filing ↗
- Section 01, Matthew Feinsod. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 28. As printed: 1,673,771. View filing ↗
- Section 01, Brett Hagen. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 28. As printed: 1,439,174. View filing ↗
- Section 01, Vikas Sinha. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 28. As printed: 1,100,954. View filing ↗
- Section 01, Matthew Gall. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 28. As printed: 1,064,607. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-17. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 02, Srinivas Akkaraju 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leone D. Patterson 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Morana Jovan-Embiricos 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Dybbs 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Napoleone Ferrara 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Hallal 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony P. Adamis 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Liisa Ann Bayko 2026-07-20. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurie Keating 2026-08-01. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy O'Leary Vandekop 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-04. Item 5.07 · say-on-pay result. As reported: 96.97% (votes for as printed: 15,852,844). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-08-13. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Kalaris Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Kalaris Therapeutics, Inc.'s own proxy. As printed: 2,569,115. View filing ↗